title: Complete atrioventricular block associated with rivastigmine therapy.
abstract: OBJECTIVE
  A case of complete atrioventricular block associated with rivastigmine use is presented.
  
  
  CONCLUSIONS
  A 67-year-old Turkish woman with Alzheimer's disease was admitted to the hospital because of dizziness and syncope. Her medical history included diagnoses of hypertension (treated with amlodipine 5 mg daily) and diabetes mellitus (treated with nateglinide 120 mg daily). She had been taking both drugs for over five years. She had also been taking rivastigmine 6 mg p.o. daily for five months for the treatment of Alzheimer's disease. She had experienced dizziness since the onset of rivastigmine therapy but had not reported it to any health care provider. On admission, she had a blood pressure measurement of 90/60 mm Hg and a pulse rate of 34 beats/min. A 12-lead electrocardiogram revealed complete atrioventricular block. Echocardiography results, blood electrolyte levels, and cardiac biochemical markers were normal. After initial evaluation, a temporary transvenous pacemaker was implanted via the right femoral vein. Amlodipine and rivastigmine were discontinued. On the first day of hospitalization, a coronary angiogram revealed normal coronary anatomy. Two days later, the complete atrioventricular block resolved spontaneously to sinus rhythm. Rivastigmine 6 mg p.o. daily was reinitiated, and complete atrioventricular block recurred on the fourth day of therapy. A VVI permanent pacemaker was implanted on the fifth day of hospitalization. Amlodipine and rivastigmine were reinitiated. The patient continued rivastigmine 6 mg p.o. daily after permanent pacemaker implantation. A three-month follow-up appointment revealed that no further syncope episodes or dizziness had occurred.
  
  
  CONCLUSIONS
  A 67-year-old woman developed complete atrioventricular block after receiving rivastigmine for the treatment of Alzheimer's disease.
authors.affiliation: Department of Cardiology, Selcuk University Medical Faculty, Konya, Turkey. mehmetkayrak@yahoo.com
authors.forename: Mehmet
authors.initials: M
authors.lastname: Kayrak
authors.forename: Mehmet
authors.initials: M
authors.lastname: Yazici
authors.forename: Selim S
authors.initials: SS
authors.lastname: Ayhan
authors.forename: Fatih
authors.initials: F
authors.lastname: Koc
authors.forename: Mehmet S
authors.initials: MS
authors.lastname: Ulgen
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy; D054537:Atrioventricular Block / Q000139:chemically induced* / Q000628:therapy; D002800:Cholinesterase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D010138:Pacemaker, Artificial; D048448:Phenylcarbamates / Q000009:adverse effects* / Q000627:therapeutic use; D000068836:Rivastigmine; D013575:Syncope / Q000139:chemically induced
chemical_list: D002800:Cholinesterase Inhibitors; D048448:Phenylcarbamates; D000068836:Rivastigmine